Estimating Bordetella pertussis seroprevalence in adolescents and young adults in Mexico using the 2012 National Health and Nutrition Survey (ENSANUT)
Estimating Bordetella pertussis seroprevalence in adolescents and young adults in Mexico using the 2012 National Health and Nutrition Survey (ENSANUT)
复制标题
DOI：
10.1016/j.vaccine.2021.08.063
复制
发表时间：
2021-09-16
期刊：
影响因子：
5.5
通讯作者：
Alpuche-Aranda, C. M.
中科院分区：
文献类型：
--
作者：
Echaniz-Aviles, G.;Garcia-Cisneros, S.;Alpuche-Aranda, C. M.
背景资料：青少年和年轻人的疫苗接种率低和百日咳感染检测不足对百日咳向婴儿的传播有影响。在这项研究中，青少年和年轻人的比例与IgG抗体对B。百日咳抗原，代表最近的感染或疫苗接种，估计在墨西哥的人口为基础的概率调查。研究方法：分析了从墨西哥2012年国家健康和营养调查中随机选择的1，581名受试者的血清和数据，其中包括1，102名青少年和479名年轻人（分别为10 - 19岁和20 - 25岁）。用CDC/FDA ELISA测定抗百日咳毒素（PT）的IgG抗体。使用Bp-IgG PT ELISA试剂盒（EUROIMMUN AG，Lubeck，德国）额外检测了234份样本的子集。来自相应检测试剂盒的阈值用于识别近期感染或疫苗接种。结果如下：总体抗PT IgG血清阳性率为3.9%（95% CI：2.3 - 6.3）;青少年为3.1%（95% CI：1.9 - 5.0），年轻成人为4.9%（95% CI：2.2 - 11）。血清阳性率没有显着差异，性别，社会经济地位，地区或农村/城市的位置。与CDC/FDA ELISA相比，EUROIMMUN检测的灵敏度为76%，特异性为88%。加权估计数代表了青少年和年轻人近期感染的相当大的负担;然而，大多数青少年和成年人是血清阴性的，因此容易感染百日咳。结论：自加强接种B.虽然墨西哥国家政策不建议幼儿期后感染百日咳，但抗PT IgG血清阳性可合理归因于近期感染。评估百日咳血清阳性率需要仔细考虑诊断测试阈值的解释和流行病学模型的使用。(c)2021 GlaxoSmithKline Biologicals S.A.由爱思唯尔有限公司出版。这是一篇开放获取的文章，使用CC BY许可证（http：//creativecommons.org/licenses/by/4.0/）。
Background: Low vaccination rates and under-detection of pertussis infections in adolescents and young adults have an impact on the transmission of pertussis to infants. In this study, the proportion of adolescents and young adults with IgG antibodies against B. pertussis antigens, representing recent infection or vaccination, was estimated in a population-based probabilistic survey in Mexico. Methods: Sera and data from 1,581 subjects, including 1,102 adolescents and 479 young adults (10-19 and 20-25 years old, respectively) randomly selected from Mexico's 2012 National Health and Nutrition Survey, were analyzed. IgG antibodies against pertussis toxin (PT) were measured with the CDC/FDA ELISA. A subset of 234 samples was additionally tested with Bp-IgG PT ELISA kit (EUROIMMUN AG, Lubeck, Germany). Threshold values from corresponding test kits were used to identify recent infection or vaccination. Results: Overall anti-PT IgG seroprevalence was 3.9% (95% CI: 2.3-6.3); 3.1% (95% CI: 1.9-5.0) in adolescents, and 4.9% (95% CI: 2.2-11) in young adults. Seroprevalence did not significantly vary by sex, socioeconomic status, region or rural/urban location. Compared to the CDC/FDA ELISA, the EUROIMMUN test showed a 76% sensitivity and 88% specificity. The weighted estimates represent a considerable burden of recent infection in adolescents and young adults; however, most adolescents and adults were seronegative and, therefore, susceptible to pertussis infection. Conclusion: Since booster vaccination to B. pertussis after toddlerhood is not recommended in the Mexican national policy, anti-PT IgG seropositivity may be reasonably attributed to recent infection. Assessing pertussis seroprevalence requires careful consideration of the diagnostic test threshold interpretation and epidemiological model used. (c) 2021 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).